Pranlukast 是半胱氨酰白三烯受体(CYSLTR1)选择性拮抗剂,有抗炎活性。
Pranlukast is an orally administered, and selective antagonist of the cysteinyl leukotrienes (LT) C(4), LTD(4) and LTE(4), used in the prophylactic treatment of chronic bronchial asthma.
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Ichiyama T, et al. Clin Exp Allergy,?003, 33(6), 802-807.
[2] Heise et al (2000) Characterization of the human cysteinyl leukotriene 2 receptor. J.Biol.Chem. 275 30531.
[3] Suzuki et al (2003) Inhibition of human eosinophil activation by a cysteinyl leukotriene receptor antagonist (Pranlukast; ONO-1078). J.Asthma 40 395.
分子式 C27H23N5O4 |
分子量 481.5 |
CAS号 103177-37-3 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 50 mM |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00410735 | Chronic Sinusitis | Drug: Placebo|Drug: Pranlukast hydrate | Ono Pharmaceutical Co. Ltd | Phase 3 | 2006-12-01 | 2012-06-12 |
NCT00127647 | Rhinitis, Allergic, Seasonal | Drug: montelukast sodium|Drug: Comparator: pranlukast | Merck Sharp & Dohme Corp. | Phase 3 | 2004-11-01 | 2017-03-17 |
NCT01539304 | Perennial Allergic Rhinitis | Drug: CITUS Dry Syrup|Drug: Placebo | SamA Pharmaceutical Co., Ltd | Phase 3 | 2010-09-01 | 2012-02-26 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们